Cambridge Nutritional Sciences (CNSL) Competitors GBX 3.59 +0.09 (+2.57%) As of 08/14/2025 10:32 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsBuy This Stock CNSL vs. CEL, OTT, BCE, FOX, CZN, CHT, DVW, BRCI, NPT, and RCIShould you be buying Cambridge Nutritional Sciences stock or one of its competitors? The main competitors of Cambridge Nutritional Sciences include Celadon Pharmaceuticals (CEL), Oxford Technology 3 Venture Capital Trust (OTT), Beacon Energy (BCE), Fox Marble (FOX), Curzon Energy (CZN), 290005 (CHT.L) (CHT), 5008 (DVW.L) (DVW), BlackRock Comms Income Inv Tst (BRCI), NetPlay TV (NPT), and RapidCloud International (RCI). These companies are all part of the "communication" industry. Cambridge Nutritional Sciences vs. Its Competitors Celadon Pharmaceuticals Oxford Technology 3 Venture Capital Trust Beacon Energy Fox Marble Curzon Energy 290005 (CHT.L) 5008 (DVW.L) BlackRock Comms Income Inv Tst NetPlay TV RapidCloud International Celadon Pharmaceuticals (LON:CEL) and Cambridge Nutritional Sciences (LON:CNSL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment. Is CEL or CNSL more profitable? Cambridge Nutritional Sciences has a net margin of -3.36% compared to Celadon Pharmaceuticals' net margin of -4,024.62%. Cambridge Nutritional Sciences' return on equity of -3.34% beat Celadon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Celadon Pharmaceuticals-4,024.62% -187.26% -34.40% Cambridge Nutritional Sciences -3.36%-3.34%-2.36% Which has stronger earnings & valuation, CEL or CNSL? Cambridge Nutritional Sciences has higher revenue and earnings than Celadon Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCeladon Pharmaceuticals£123.38K66.61-£4.97M-£7.98-1.68Cambridge Nutritional Sciences£9.77M0.87-£3.03MN/AN/A Which has more volatility & risk, CEL or CNSL? Celadon Pharmaceuticals has a beta of -0.26, indicating that its share price is 126% less volatile than the S&P 500. Comparatively, Cambridge Nutritional Sciences has a beta of 3.89, indicating that its share price is 289% more volatile than the S&P 500. Do institutionals and insiders have more ownership in CEL or CNSL? 10.7% of Celadon Pharmaceuticals shares are held by institutional investors. Comparatively, 10.2% of Cambridge Nutritional Sciences shares are held by institutional investors. 65.1% of Celadon Pharmaceuticals shares are held by insiders. Comparatively, 10.9% of Cambridge Nutritional Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media favor CEL or CNSL? In the previous week, Celadon Pharmaceuticals' average media sentiment score of 0.00 equaled Cambridge Nutritional Sciences'average media sentiment score. Company Overall Sentiment Celadon Pharmaceuticals Neutral Cambridge Nutritional Sciences Neutral SummaryCambridge Nutritional Sciences beats Celadon Pharmaceuticals on 6 of the 10 factors compared between the two stocks. Get Cambridge Nutritional Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CNSL and its competitors with MarketBeat's FREE daily newsletter. Email Address CNSL vs. The Competition Export to ExcelMetricCambridge Nutritional SciencesMedical Instruments & Supplies IndustryMedical SectorLON ExchangeMarket Cap£8.54M£3.09B£5.61B£3.09BDividend YieldN/A1.99%4.61%5.04%P/E Ratio-362.1017.7330.29169.94Price / Sales0.87336.78463.41289,809.18Price / CashN/A146.5438.2127.94Price / Book0.902.388.825.22Net Income-£3.03M£99.80M£3.25B£5.89B7 Day Performance-1.37%0.97%3.70%-0.31%1 Month Performance-0.72%-2.91%5.84%0.43%1 Year PerformanceN/A120.34%29.92%61.66% Cambridge Nutritional Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNSLCambridge Nutritional SciencesN/AGBX 3.59+2.6%N/A-0.9%£8.54M£9.77M-362.103,200Gap UpCELCeladon PharmaceuticalsN/AGBX 13.40flatN/AN/A£8.22M£123.38K-1.682,780OTTOxford Technology 3 Venture Capital TrustN/AN/AN/AN/A£2.13M-£85K-12.59203Gap DownBCEBeacon EnergyN/AGBX 0flatN/AN/A£740KN/A-0.3544,600FOXFox MarbleN/AGBX 0.04flatN/A-97.4%£159K£722.06K-135.0010,600CZNCurzon EnergyN/AN/AN/AN/A£34KN/A-3.4014,700Gap DownCHT290005 (CHT.L)N/AN/AN/AN/A£0.00N/A0.0020,300DVW5008 (DVW.L)N/AN/AN/AN/A£0.00N/A0.00N/AGap UpBRCIBlackRock Comms Income Inv TstN/AN/AN/AN/A£0.00N/A0.00N/AHigh Trading VolumeNPTNetPlay TVN/AN/AN/AN/A£0.00N/A0.00147,000RCIRapidCloud InternationalN/AN/AN/AN/A£0.00N/A0.0023,000 Related Companies and Tools Related Companies Celadon Pharmaceuticals Competitors Oxford Technology 3 Venture Capital Trust Competitors Beacon Energy Competitors Fox Marble Competitors Curzon Energy Competitors 290005 (CHT.L) Competitors 5008 (DVW.L) Competitors BlackRock Comms Income Inv Tst Competitors NetPlay TV Competitors RapidCloud International Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:CNSL) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cambridge Nutritional Sciences plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Cambridge Nutritional Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access